Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.27 Million | -9.31 Million | -42.49 Million | -79.06 Million | -61.49 Million | -35.7 Million |
| Net Income | -12.82 Million | -14.68 Million | -38.28 Million | -81.4 Million | -81.03 Million | -51.59 Million |
| Depreciation & Amortization | 423 Thousand | 406 Thousand | 387 Thousand | 89 Thousand | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | 2.69 Million |
| Change in working capital | 1.2 Million | -1.85 Million | -12.2 Million | -3.81 Million | 10.12 Million | 10.09 Million |
| Other non-cash items | -427 Thousand | 6.81 Million | 7.6 Million | 6.06 Million | 9.41 Million | 3.1 Million |
| Investing Cash Flow | - | - | - | -218 Thousand | -1.76 Million | - |
| Investments in PPE | - | - | - | -218 Thousand | -1.76 Million | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1 Million | 544 Thousand | 5.67 Million | 8.38 Million | 51.21 Million | 168.65 Million |
| Debt repayment | -1 Million | -5.3 Million | -5.3 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 5.84 Million | 371 Thousand | 8.38 Million | 54.28 Million | 180.13 Million |
| Other Financing Activities | - | -10.6 Million | 10.6 Million | 8388.00 | -3.06 Million | -11.47 Million |
| Accounts receivables | 89 Thousand | -37 Thousand | 65 Thousand | 496 Thousand | -629 Thousand | -38 Thousand |
| Accounts payables | 1.11 Million | -1.81 Million | -12.27 Million | -4.31 Million | 10.75 Million | 10.13 Million |
| Inventory | - | 1816.00 | 12.27 Thousand | 4314.00 | -10.75 Thousand | - |
| Other working capital | 925 Thousand | -1816.00 | -12.27 Thousand | -4314.00 | 10.75 Thousand | 10.13 Million |
| Cash at beginning of period | 13.57 Million | 21.71 Million | 58.5 Million | 129.5 Million | 141.54 Million | 8.38 Million |
| Cash at end of period | 3.16 Million | 13.57 Million | 21.71 Million | 58.5 Million | 129.5 Million | 141.54 Million |
| Capital Expenditure | - | - | - | -218 Thousand | -1.76 Million | - |
| Effect of forex changes on cash | -144 Thousand | 637 Thousand | 42 Thousand | -106 Thousand | 17 Thousand | 205 Thousand |
| Net cash flow / Change in cash | -10.41 Million | -8.13 Million | -36.78 Million | -71 Million | -12.03 Million | 133.15 Million |
| Free Cash Flow | -11.27 Million | -9.31 Million | -42.49 Million | -79.28 Million | -63.26 Million | -35.7 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.67 Million | -12.82 Million | -1.67 Million | -4.74 Million | -4.74 Million | -14.68 Million |
| Depreciation & Amortization | 102 Thousand | 423 Thousand | 102 Thousand | 109.5 Thousand | 109.5 Thousand | 406 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 562.5 Thousand | 1.2 Million | 562.5 Thousand | 39 Thousand | 39 Thousand | -1.85 Million |
| Other non-cash items | -90.5 Thousand | -427 Thousand | -90.5 Thousand | 55.5 Thousand | 55.5 Thousand | 6.81 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 500 Thousand | 1 Million | 500 Thousand | - | - | 544 Thousand |
| Debt repayment | - | -1 Million | - | - | - | -5.3 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 5.84 Million |
| Other Financing Activities | 500 Thousand | - | 500 Thousand | - | - | -10.6 Million |
| Accounts receivables | 74 Thousand | 89 Thousand | 74 Thousand | -29.5 Thousand | -29.5 Thousand | -37 Thousand |
| Accounts payables | - | 1.11 Million | - | - | - | -1.81 Million |
| Inventory | - | - | - | - | - | 1816.00 |
| Other working capital | 488.5 Thousand | 925 Thousand | 488.5 Thousand | 68.5 Thousand | 68.5 Thousand | -1816.00 |
| Cash at beginning of period | 783.21 Thousand | 13.57 Million | 783.21 Thousand | 4.41 Million | 4.41 Million | 21.71 Million |
| Cash at end of period | -784.00 | 3.16 Million | -784.00 | -4424.00 | -4424.00 | 13.57 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -188 Thousand | -144 Thousand | -188 Thousand | 116 Thousand | 116 Thousand | 637 Thousand |
| Net cash flow / Change in cash | -784 Thousand | -10.41 Million | -784 Thousand | -4.42 Million | -4.42 Million | -8.13 Million |
| Free Cash Flow | -1.09 Million | -11.27 Million | -1.09 Million | -4.54 Million | -4.54 Million | -9.31 Million |
EPBIO
API
688113
301004
DAVA
322000